With A $1.2 Billion Hammer,  The FTC Closes Loophole To Prevent Generic Drugs

This morning, the U.S. Federal Trade Commission drew blood: Teva Pharmaceuticals will pay $1.2 billion to reimburse insurers, drug wholesalers, and pharmacies who paid full price for the Provigil, produced by Cephalon, a company Teva bought in 2011, because Cephalon had paid generic drugmakers to delay launching cheaper versions of
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news